Given the compensation of eicosanoid production by COX-1 pathway [4], the possibility of utilizing nonspecific COX [4], [6], [10] plus MIF [16], [18], [26] inhibitors for cancer prevention and therapy cannot be ruled out. Here, MIF is linked to cancer.